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S U M M A R Y
Objective: To describe the burden and the predictors of genital warts (GWs) in Czech men and women.
Methods: A population-based cross-sectional study was conducted of 32 974 randomly selected health
clinic attendees from all 14 regions of the Czech Republic. Information on GWs and lifestyle behaviour
was collected using a questionnaire.
Results: Results revealed a 5.8% prevalence rate of self-reported GWs in the Czech population aged 16–
55 years. There was an increase in the incidence of GWs in the years 2010–2013 when compared to
lifetime incidence rates, from 205.4 (95% conﬁdence interval (CI) 191.0–219.7) to 441.8 (95% CI 393.1–
490.6) per 100 000 person-years. No signiﬁcant differences were observed between genders. The
strongest risk factors found for GWs were an infected sexual partner (adjusted odds ratio (OR) 114.3, 95%
CI 78.9–165.4) and a high number of lifetime sexual partners (adjusted OR 3.36, 95% CI 2.72–4.17 for >14
partners vs. one partner). A novel ﬁnding was that 22.7% (95% CI 20.9–24.6%) of participants claimed that
the pathology had disappeared spontaneously without medical assistance.
Conclusions: The results provide baseline information for the development and monitoring of prevention
strategies against GWs in the Czech Republic.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Genital human papillomavirus (HPV) causes broad morbidity
among men and women, ranging from cancer to genital warts
(GWs). Although the latter disease is not life-threatening, the
lesions can cause not only clinical symptoms, such as burning,
itching, bleeding, and pain, but also psychosocial stress, embar-
rassment, and anxiety.1,2 Two HPV types (HPV6 and 11) cause up to
90% of all GWs cases.3
Links between GWs and various health-related behaviours and
lifestyle factors have been suggested by other investigators, and
there is now widespread concern regarding the growing problem
of GWs.4–6 Despite the existence of several works on the
prevalence and incidence of GWs, only a few have provided data
on the general population.5,7,8 As such, new knowledge on the
overall rates and dynamic acquisition of GWs in the general
population is crucial in order to develop national strategies to
control and prevent HPV infection. This has become even more
relevant since a prophylactic quadrivalent vaccine (4HPV) against
HPV6, 11, 16, and 18 has become available.9 The same prevention* Corresponding author. Tel.: +420 777 324 641.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).of GWs is expected from new 9-valent HPV vaccine, which includes
the HPV types in the 4HPV vaccine and ﬁve additional oncogenic
types (31, 33, 45, 52, and 58).10 Of note, the absence of a response
against antigens HPV6 and 11 indicated that the bivalent vaccine
(2HPV) against HPV16 and 18 could never fully control GWs. For
this reason, routine HPV vaccination in the United Kingdom was
switched from the bivalent to the quadrivalent vaccine.
The objective of this study was to describe the prevalence and
incidence rates of GWs in the Czech Republic using a questionnaire
survey that captures a larger cross-section of the general
population than clinic-based data. The study also sought to
identify and evaluate predictors for the pathology.
2. Materials and methods
2.1. Study population
A cross-sectional survey on GWs was conducted in all 14 regions
of the Czech Republic. Volunteers were recruited randomly from
people attending outpatient health clinics and were offered a
paper-based self-administered questionnaire. To guarantee conﬁ-
dentiality, participants were asked to seal the completed
questionnaire in an envelope supplied for this purpose. Physicians
or parents could complete the survey for children or adolescentsciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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1500 participants from each region.
Between January 2013 and March 2014, valid data were
collected from 32 974 attendees at 268 outpatient clinics who
agreed to engage in the survey. Paediatricians (n = 166), gynaecol-
ogists (n = 57), and other specialists including dermatologists and
allergists (n = 45) were involved, as well as immunization and
transfusion centres. The percentage of subjects in each region
ranged from 5% to 11%. The study was approved by the Executive
Committee of Preventive Medicine at Charles University in Prague.
2.2. Data collection
The questionnaire enquired on several lifestyle factors,
including residence (rural or urban), education, smoking (age
when ﬁrst started smoking and number of cigarettes per day),
number of lifetime sexual partners, and HPV immunization status
(also type of commercial HPV vaccine received, year of last dose,
and if they had received all three doses), as well as date of birth and
gender.
Information on GWs was obtained with the question, ‘‘Have you
ever had genital warts?’’ Study participants were also asked for the
year of their ﬁrst outbreak of GWs and of recurrent episodes if any
occurred, the treatments received, and the GWs status of their
sexual partner. The questionnaire also contained six illustrative
pictures representing three different types of GWs for men and
women, from which the respondents had to choose the one most
similar to theirs.
2.3. Statistical analysis
The overall and age-speciﬁc lifetime prevalence of self-reported
GWs was estimated with a 95% conﬁdence interval (CI). Associa-
tions between the various lifestyle factors and GWs were
examined using univariate and multiple logistic regression, from
which odds ratios (ORs) and the corresponding 95% CIs were
estimated. The multivariate analysis of the effects of different
lifestyle factors on GWs prevalence was initially performed
separately for the two genders, but data were later pooled as no
statistically signiﬁcant differences were found between the two
gender groups.
Incidence rates were calculated as the number of GWs claims
divided by the total person-years at risk (reported per 100 000
person-years). Person-time started to accumulate at birth and
ended at the date of the ﬁrst GWs episode, or, if none had occurred,
at the survey date.
Analyses were performed using StatsDirect Statistical Software,
version 3.0.117 (StatsDirect Ltd, UK).
3. Results
Study participants had a mean age of 35.8 years (95% CI 35.7–
35.9 years), with only 1.0% (95% CI 0.9–1.1%) aged 15 years or
younger and less than 6% older than 56 years of age (up to 80 years
of age). Most of the participants were in the age group 16–55 years,
i.e. 93.1% (95% CI 92.9–93.4%). Subjects were studied in 5-year age
groups. The study population consisted predominantly of women
(81.4%, 95% CI 81.0–81.8%).
Current smoking was 25.2% (95% CI 24.7–25.6%) and was more
frequent in men than in women (age adjusted OR 1.4, 95% CI 1.3–
1.5). More than 90% of adults aged 23 years or older had a
minimum basic level of schooling of 13 years (high school). The
median lifetime number of sexual partners was three for both
genders, with a mean of 11.1 (95% CI 6.0–16.2) for men and 4.3
(95% CI 4.2–4.3) for women. While the majority of the study
population lived in urban areas (77.7%; 95% CI 77.2–78.2%), therewas no difference in age distribution between urban and rural
residents (age adjusted OR 1.0, 95% CI 0.97–1.03).
Interestingly, despite the low HPV vaccination rate in the study
population (7.2%, 95% CI 6.9–7.5%), 29.4% (95% CI 28.1–30.7%) of
girls and young women aged 11–25 years had been immunized.
Although the HPV vaccination rate of men was submarginal, i.e.
0.8% (95% CI 0.6–1.1%), no man reported the acquisition of GWs
after immunization.
Overall, 1968 participants (6.0%, 95% CI 5.7–6.2%) reported one
or more episodes of GWs. The lifetime prevalence of self-reported
GWs was independent of gender, with rates of 5.7% (95% CI 5.2–
6.3%) for men and 6.0% (95% CI 5.7–6.3%) for women. The
prevalence rate was not different between men and women with
regard to their age, number of sexual partners or sexual partner
having ever had GWs, area of residence, or smoking habit (Table 1).
Of the participants with clinically diagnosed GWs, 76.2% (74.3–
78.1%) reported having required treatment with topical cytotoxic
agents and/or ablative techniques, while 22.7% (95% CI 20.9–24.6%)
claimed that the pathology disappeared without medical assis-
tance.
The prevalence of self-reported GWs increased with age,
peaking at 7.6% (95% CI 6.9–8.4%) in the age group 26–30 years,
after which it declined to 4.9% (95% CI 4.0–6.0%) in the oldest age
group. The sex-, age- and region-standardized GWs prevalence rate
reached 5.8% (95% CI 5.4–6.2%) in the Czech population aged 16–55
years.
The lifetime incidence rate of GWs per 100 000 persons-years
was 165.7 (95% CI 158.4–173.1) for the study participants and
141.6 (95% CI 158.4–173.1) for the Czech population. This rate
increased to 291.6 (95% CI 278.7–305.1) in the study and 205.4
(95% CI 191.0–219.7) in the Czech population when only
individuals aged 16–55 years were considered. A slightly lower
incidence was found in men than in women, but this was not
statistically signiﬁcant, i.e. OR 1.11 (95% CI 0.99–1.26) for study
participants and 1.12 (95% CI 0.97–1.28) for the Czech population.
The sex- and age-standardized incidence rate between the
years 2010 and 2013 was 441.8 (95% CI 393.1–490.6) per 100 000
persons-years at risk, revealing an increasing tendency for GWs
infection among the population aged 16–55 years during this
period when compared with lifetime rates. This observation was
further supported by the increase, in 2013, of ﬁrst GWs infections:
up to 0.83% (95% CI 0.67–1.03%) among subjects aged 16–35 years
and 0.58% (95% CI 0.47–0.70%) among those between 16 and
55 years of age.
Figure 1 shows the lifetime incidence rate of self-reported GWs
by gender and age. The highest incidence in attendees with a
history of GWs was found in the age group 21–25 years (459.2, 95%
CI 424.9–495.6 per 100 000 person-years). No signiﬁcant
differences were observed between men and women, except in
two age groups: the group of subjects between 16 and 20 years of
age in which more women than men reported a ﬁrst episode of
GWs, and the group aged 31–35 years in which the exact opposite
occurred.
Risk factors were estimated for both genders independently
because no signiﬁcant differences in GWs prevalence were
observed between men and women.
A sexual partner with GWs was identiﬁed as the strongest risk
factor for the acquisition of infection (Table 2). The percentage of
subjects reporting GWs in both members of the couple was 87.6%
(83.2–91.3%), and the mutually adjusted OR, independent of
gender, achieved 114.3 (95% CI 78.9–165.4) when compared to
participants whose sexual partners had never had the infection.
The second most important predictor of GWs was the lifetime
number of sexual partners; the risk of infection was found to
increase with the number of partners. The highest GWs prevalence
(13.2%, 95% CI 11.5–15.1%) was among subjects who had had more
Table 1
Prevalence rates of self-reported genital warts in men and women, related to predictors
Category, parameter Men Women ORa
No. % with GWs No. % with GWs
GW status of sexual partner
Negative 6089 5.0 (4.5–5.6) 26 610 5.3 (5.1–5.6) 0.95 (0.83–1.07)
Positive 48 93.8 (82.8–98.7) 227 86.3 (81.2–90.5) 2.47 (0.82–7.39)
Age, years
15 64 3.1 (0.4–10.8) 255 1.2 (0.2–3.4) 0.96 (0.85–1.08)
16–20 463 2.6 (1.3–4.5) 1794 5.1 (4.1–6.2)
21–25 529 6.8 (4.8–9.3) 2647 7.5 (6.5–8.6)
26–30 807 7.1 (5.4–9.1) 3781 7.7 (6.9–8.6)
31–35 1105 5.9 (4.6–7.4) 5672 6.1 (5.5–6.7)
36–40 1228 5.9 (4.7–7.4) 5549 5.6 (5.0–6.2)
41–45 799 6.4 (4.8–8.3) 3009 5.7 (4.9–6.6)
46–50 465 4.1 (2.5–6.3) 1634 5.8 (4.7–7.1)
51–55 271 5.9 (3.4–9.4) 961 3.6 (2.5–5.0)
56 406 4.9 (3.0–7.5) 1535 5.0 (3.9–6.2)
Lifetime No. of sexual partners
0 139 1.4 (0.2–5.1) 411 1.7 (0.7–3.5) 0.84 (0.24–2.90)
1 1402 3.1 (2.2–4.1) 6429 3.5 (3.1–4.0) 0.87 (0.63–1.21)
2–4 1097 5.4 (4.1–6.9) 7143 5.1 (4.6–5.7) 1.05 (0.79–1.39)
5–9 901 7.8 (6.1–9.7) 4572 7.6 (6.8–8.4) 1.02 (0.78–1.33)
10–14 458 7.0 (4.8–9.7) 1429 9.4 (8.0–11.1) 0.76 (0.51–1.13)
15 548 10.6 (8.1–13.5) 834 15.0 (12.6–17.6) 0.69 (0.48–1.01)
Smoking, cigarettes-day
Never or 1 4335 5.1 (4.5–5.8) 20 558 5.4 (5.1–5.8) 0.96 (0.83–1.11)
2–10 890 6.7 (5.2–8.6) 4255 7.4 (6.6–8.2) 0.92 (0.69–1.22)
>10 726 7.2 (5.4–9.3) 1203 10.4 (8.7–12.3) 0.69 (0.47–1.02)
Residence
Rural 956 5.3 (4.0–7.0) 4917 4.9 (4.3–5.5) 1.14 (0.83–1.55)
Urban 3701 5.6 (4.9–6.4) 16 722 6.0 (5.7–6.4) 0.93 (0.80–1.09)
HPV immunization
No 6091 5.8 (5.2–6.4) 24 711 6.3 (6.0–6.6) 0.92 (0.82–1.04)
2HPV 9 0.0 (0.0–33.6) 816 6.7 (5.1–8.7) NA
4HPV 19 0.0 (0.0–17.7) 1113 0.6 (0.3–1.3) NA
OR, odds ratio; GWs, genital warts; HPV, human papillomavirus; NA, not applicable.
a Age-adjusted OR between men and women.
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compared to those with just one sex partner.
Other risk factors were being in the age group 21–30 years,
smoking more than 10 cigarettes a day, and living in an urban area.
Data also appeared to indicate a link between lifestyle and health-
related behaviour and lifetime number of sexual partners. In fact,
the percentage of heavy smokers with ﬁve or more lifetime sexual
partners (40.6%, 95% CI 38.4–42.9%) was 1.7 times that of the non-
smokers with the same number of partners (24.2%, 95% CI 23.6–
24.7). The OR between them was 2.14 (95% CI 1.95–2.36). Reports
of at least ﬁve lifetime sexual partners were also more frequent
among participants from urban areas (28.2%, 95% CI 28.2–29.4%)
than those from rural locations (21.7%, 95% CI 20.6–22.8%), i.e. OR
1.5 (95% CI 1.4–1.6).Figure 1. Lifetime incidence rate of self-repImmunization with the 4HPV vaccine, on the other hand,
substantially decreased the prevalence of GWs, especially among
young women. The percentage of 4HPV-immunized women who
went on to develop GWs was reduced by 91.2% (95% CI 81.8–96.7%)
and 91.8% (95% CI 83.0–96.9%) when compared to the unvaccinat-
ed and 2HPV-vaccinated, respectively. Thus, only immunization
with 4HPV can be considered a protective factor against the
acquisition of GWs.
Although only 0.6% (95% CI 0.5–0.7%) of all individuals reported
recurrent disease, the percentage in the affected group increased to
9.5% (95% CI 8.2–10.9). In fact, it was also found that the risk of
recurrence was higher than that of a ﬁrst infection (age-adjusted
OR 1.60, 95% CI 1.37–1.88), and it was not inﬂuenced by gender
(age-adjusted OR 0.99, 95% CI 0.66–1.46).orted genital warts by gender and age.
Table 2
Predictors associated with self-reported genital warts
Category, parameter No. % with GWs ORa ORb
GW status of sexual partner
Negative 32 699 5.3 (5.0–5.5) 1.0 1.0
Positive 275 87.6 (83.2–91.3) 127.58 (88.3–184.2) 114.25 (78.9–165.4)
Age, years
15 319 1.6 (0.5–3.6) 0.33 (0.13–0.82) 0.55 (0.22–1.38)
16–20 2257 4.6 (3.7–5.5) 1.0 1.0
21–25 3176 7.4 (6.5–8.4) 1.67 (1.32–2.12) 1.33 (1.03–1.72)
26–30 4588 7.6 (6.9–8.4) 1.72 (1.37–2.16) 1.29 (1.01–1.65)
31–35 6777 6.0 (5.5–6.6) 1.34 (1.08–1.68) 0.99 (0.78–1.26)
36–40 6777 5.7 (5.1–6.2) 1.26 (1.01–1.57) 0.97 (0.76–1.23)
41–45 3808 5.8 (5.1–6.6) 1.29 (1.02–1.65) 0.98 (0.75–1.26)
46–50 2099 5.4 (4.5–6.5) 1.20 (0.91–1.58) 0.98 (0.73–1.31)
51–55 1232 4.1 (3.1–5.4) 0.90 (0.64–1.27) 0.72 (0.50–1.03)
56 1941 4.9 (4.0–6.0) 1.09 (0.82–1.45) 0.98 (0.73–1.33)
Lifetime No. of sexual partners
0 550 1.6 (0.8–3.1) 0.61 (0.30–1.26) 0.64 (0.32–1.28)
1 7831 3.5 (3.1–3.9) 1.0 1.0
2–4 8240 5.1 (4.7–5.6) 1.50 (1.28–1.75) 1.37 (1.17–1.62)
5–9 5473 7.6 (6.9–8.3) 2.24 (1.91–2.63) 2.04 (1.73–2.41)
10–14 1887 8.9 (7.6–10.2) 2.41 (2.13–3.20) 2.34 (1.89–2.89)
15 1382 13.2 (11.5–15.1) 4.13 (3.39–5.05) 3.36 (2.72–4.17)
Smoking, cigarettes-day
Never or 1 24 893 5.4 (5.1–5.7) 1.0 1.0
2–10 5145 7.3 (6.6–8.0) 1.35 (1.19–1.52) 1.14 (1.00–1.29)
>10 1929 9.2 (7.9–10.6) 1.74 (1.48–2.05) 1.33 (1.11–1.59)
Residence
Rural 5874 5.0 (4.4–5.6) 1.0 1.0
Urban 20 425 6.0 (5.6–6.3) 1.22 (1.07–1.39) 1.19 (1.03–1.36)
HPV immunization
No 30 802 6.2 (5.9–6.5) 1.0 1.0
2HPV 825 6.7 (5.1–8.6) 1.01 (0.76–1.35) 1.17 (0.86–1.58)
4HPV 1132 0.6 (0.2–1.3) 0.10 (0.05–0.20) 0.09 (0.04–0.20)
GWs, genital warts; OR, odds ratio; HPV, human papillomavirus. Note: Missing values were excluded from the analysis.
a Adjusted for age.
b All factors mutually adjusted.
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This is the ﬁrst representative study of GWs in the general
population of the Czech Republic. Overall, 6.1% of sexually active
persons aged 16 to 55 years reported GWs.
Other studies involving self-report have found the lifetime
prevalence of GWs to range from 4.0% or 4.4% in Australian men or
women aged 16–59 years,11 to 5.6% in US nationals aged 18–59
years.12 Slightly higher prevalences were found among Danish
women and men aged 18–45 years (10.6% and 7.9%),13,14 as well as
among women of the same age in Iceland (12.0%), Norway (9.5%),
and Sweden (11.3%). The estimates in the present study of 5.8% for
GWs prevalence in Czech men and 6.1% for Czech women are close
to the midpoint of previously published values.
In the present study, the GWs incidence rate of 0.83% in those
aged 16–35 years who experienced a ﬁrst GWs episode in the year
2013, was similar to that documented in 2010 for Czech women.15
These numbers are slightly higher than the annual incidence rates
per 100 000 sexually active persons reported in the United
Kingdom,16 France,17 Spain,18 and Germany,19 but still lower than
the percentages of newly acquired GWs per year reported in
women in the Nordic countries, i.e. 1.3% in Denmark, 1.9% in
Iceland, 1.1% in Norway, and 1.0% in Sweden.14
In agreement with the results of others studies,12,20 the peak
occurrence of GWs in men seen in the present study occurred
slightly later in life than that in women. As found in a study from
the USA, no statistically signiﬁcant differences in GWs prevalence
or incidence rates were identiﬁed between adult men and
women.21 However, the results of other surveys have already
suggested higher incidence rates in men than women,18,20 as well
as the opposite.12,19Besides methodological differences in study design, differences
in the epidemiology of GWs between countries can be explained by
geographical and cultural variations in sexual behaviour. In
addition, epidemiological knowledge across the world has shown
an increasing trend in the occurrence of GWs in the last 30–40
years;14,20,22 this could also have contributed to the different rates
estimated in distinct years over the last 15 years.
Sexual behaviour was found to be the strongest risk predictor
for GWs burden in both men and women. This is the ﬁrst study to
estimate the risk of acquiring GWs when having an infected sexual
partner. The probability of contracting GWs in these circumstances
was found to be almost 17 times higher than with a non-infected
partner. In fact, there was an 87.6% chance of becoming infected as
well, independent of gender.
An increased risk was also observed in men or women who
reported having had at least two to four lifetime sexual partners in
comparison to those who reported having had one or no sexual
partner. Consistent with other studies, the risk of GWs was found
to increase with an increasing number of sexual partners.12–14
Individuals with a prior history of GWs were identiﬁed as being
1.8 times more susceptible to a new infection than those with no
previous episodes.
It was also discovered that the frequency of GWs correlated
with health-related behaviours (heavy smoking) and demographic
variables (urban residence). Although both predictors appeared to
be risk factors for the acquisition of GWs, heavy smokers and those
living in urban areas also reported ﬁve or more lifetime sexual
partners more frequently than other participants. Therefore it is
uncertain whether smoking and residence are confounding or risk
factors for GWs. This could also explain why the association
between smoking and GWs incidence has been inconsistent across
M. Petra´sˇ, V. Ada´mkova´ / International Journal of Infectious Diseases 35 (2015) 29–33 33studies, with some reporting a positive correlation between
smoking and the GWs burden,13,14,23,24 while others have found
no such correlation.25,26
To our knowledge, this is the ﬁrst published survey to include
immunization with the quadrivalent HPV vaccine as a protective
predictor. It is clear that this vaccine contributes to a substantial
reduction in GWs burden;27–29 at least 90% of individuals were
protected against the disease after vaccination in comparison to
those not vaccinated or immunized with the bivalent HPV vaccine.
A potential limitation of this survey was the lack of a system to
routinely register sexually transmitted infections, like that existing
in the United Kingdom,30 in order to conﬁrm the self-reported
sexual behaviour. Despite a high participation rate, the possibility
of bias pertaining to non-attendance or interview bias cannot be
excluded. Another limitation was the absence of information on
other health-related or demographic variables as reported in other
studies, such as marriage status, other sexually transmitted
infections, pregnancy history, contraceptive use, alcohol consump-
tion, contact with a prostitute, etc.
Nevertheless, this epidemiological survey still has much
relevance. First, it is the largest study so far to assess the
occurrence of GWs in Czech men and women. Second, it is a
nationwide investigation with randomized data from the general
population in all 14 regions of the Czech Republic. Third, HPV
immunization has only recently been established as a predictor of
the disease and had not been studied. Fourth, the survey, in
contrast to most studies, was not limited to individuals with
clinically diagnosed GWs; this enabled attendees to self-diagnose
using the pictures included in the questionnaire.
Interestingly, while treatment was refused by only 10% of those
infected in the USA and 7.4% in Australia,4,31 in the present study
almost 23% of attendees did not require treatment for GWs, most
likely because they were not aware of the infection.
In conclusion, this study showed the overall prevalence of GWs
in the Czech population aged 16–55 years to be 5.8%; however,
incidence rates are rising fast, as demonstrated by the growing
number of cases per year, increasing from an average of
205.4 lifetime cases to 441.8 cases per 100 000 person-years
between 2010 and 2013. As such, vaccination against HPV types
6 and 11 together with types 16 and 18, or eventually with
additional types 31, 33, 45, 52, and 58 (and not just HPV16 and 18)
must become more widely adopted, because this is the only highly
effective instrument against what is an increasingly problematic
situation. Because GWs are not restricted to women, the absence of
routine immunization for boys and the routine immunization of
13-year-old Czech girls with any type of HPV vaccine will no longer
be sufﬁciently effective to control this disease.
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